Elosulfase Alfa (Vimizim®)

Vimizim (elosulfase alfa) is covered only for FDA‑approved treatment of MPS IVA (Morquio A) and is not covered for other or off‑label indications. Coverage requires confirmatory testing (deficient N‑acetylgalactosamine‑6‑sulfatase activity in leukocytes/fibroblasts or pathogenic GALNS genetic mutation), prescription by or consultation with a geneticist/endocrinologist/metabolic/lysosomal storage disorder specialist, dosing ≤2 mg/kg IV no more than once weekly, documentation of tests/specialist involvement, and approval is time‑limited to 12 months.

"Vimizim (elosulfase alfa) is indicated for the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)."

Sign up to see full coverage criteria, indications, and limitations.